Canaccord Genuity Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Negative 54.4%

Neg 54.4% Neu 0% Pos 0%

Canaccord Genuity analyst Edward Nash maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and lowers the price target from $9 to $5.